WeedLife News Network

Hot off the press cannabis, marijuana, cbd and hemp news from around the world on the WeedLife News Network.

CBD of Denver expands into Europe's largest cannabis market

CBD of Denver, Inc. (OTC Pink: CBDD), a distributor of CBD and unique CBD products sold in Switzerland and throughout Europe, is pleased to announce its expansion into the German medical cannabis market with the hiring of Bijan Hezarkhani to lead CBD of Denver's growth in this fast growing European market. Bijan has extensive experience in the cannabis industry, including building out a medical cannabis franchise in Germany. He was the business development manager for Khiron Life Sciences for the last three years, visiting doctors and pharmacies in Germany to build Khiron's medical cannabis business. Previously, he spent time at Canopy Growth as a business analyst covering Europe. Bijan will be the head of the Company's medical cannabis sales in Germany and will be based in Frankfurt.

Germany officially approved medical cannabis in 2017. Germany is the largest medical cannabis market in Europe at 15 tonnes annually and generated approximately US$300 million of revenue in 2021. According to Forbes Magazine, over a million patients in Germany will have access to medical cannabis by 2024, with the German medical market worth €7.7 billion by 2028.

The German market appears to be moving closer to adult-use legalisation, a market estimated at 400 tonnes annually, making it critical to have the infrastructure in place in country. With 83 million people, Germany is the most attractive market in Europe for cannabis. CBD of Denver believes the leaders in the German adult-use market will be those companies already having exposure to the legal market.

The medical market in Germany is import driven and requires an experienced sales force to facilitate the education process around different products.

"This is a seismic moment in the history of our company. Our expansion into the German medical cannabis market is a key part of our new strategy to diversify our revenue streams. This gives our company exposure to the largest cannabis market in Europe and allows us to expand out of our core in Switzerland," said CBD of Denver CEO Paul Gurney.

e-mail icon
Continue reading

Local cannabis study to determine efficacy of CBD oil

It is hoped a Shepparton research project will unearth answers on the effects of cannabis oils in cannabis users.

The 12-week project is seeking anonymous participants to determine the efficacy of Cannabidiol oil for mood and sleep issues in cannabis users.

The study, led by Shepparton-based Professor Edward Ogden, will include 33 participants who will meet with a researcher monthly to record results.

CBD oil is an alternative therapy which has promising results in trials for treating addiction around the world.

CBD, unlike Tetrahydrocannabinol — the other main compound found in marijuana — contains no psychoactive or addictive qualities.

“Recreational marijuana is very high in THC and we are seeing an increasing amount of people suffering from cannabis use disorder — a condition defined by severe dependence, cravings and withdrawals,” research assistant Coco Piesse said.

e-mail icon
Continue reading

States that legalized marijuana now researching mental health risks of high-potency cannabis

Products like wax and shatter can have THC levels up to 90 percent, and states like Washington and Colorado are looking at potency caps and product warnings.

With national cannabis legalization poised to be introduced in the Senate, states that legalized recreational marijuana 10 years ago are now studying the public health implications of a variety of new high-potency products amid questions about a possible link to psychosis.

The newer products are called marijuana concentrates and are commonly known as wax and shatter. They can have levels of THC, the psychoactive component of marijuana, as high as 85 percent to 90 percent. By comparison, researchers say, the marijuana level in a typical joint 20 years ago was closer to 5 percent. States like Washington and Colorado are now considering product warnings or potency caps to limit access.

At a January forum, the director of the National Institute on Drug Abuse, Dr. Nora Volkow, raised concerns that teens are increasingly vaping high-potency cannabis.

Volkow said she worries that “huge concentrations” of THC could have serious consequences.

“We are seeing a very significant rise in psychosis associated with the consumption of marijuana,” she said.

e-mail icon
Continue reading

Tips for seniors trying cannabis for the first time

 

No matter how old you are, cannabis is a fantastic aid that will help make the aging process much simpler for both men and women.

Seniors are part of the fastest growing demographic of cannabis consumers. The growing population of older cannabis users find great relief in the natural benefits offered by cannabis, whether they choose CBD products or those with THC. It makes sense, as cannabis is a wonderful natural solution for many ailments that afflict the elderly.

According to a study conducted by researchers from the University of California San Diego School of Medicine, seniors use marijuana mainly for treating medical conditions such as insomnia, anxiety, depression, and pain. “Surprisingly, we found that nearly three-fifths of cannabis users reported using cannabis for the first time as older adults. These individuals were a unique group compared to those who used cannabis in the past,” explains the study’s co-author, Kevin Yang.

“New users were more likely to use cannabis for medical reasons than for recreation. The route of cannabis use also differed with new users more likely to use it topically as a lotion rather than by smoking or ingesting as edibles. Also, they were more likely to inform their doctor about their cannabis use, which reflects that cannabis use is no longer as stigmatized as it was previously,” he adds.

Aside from that, cannabis use can also help you age gracefully. It can also be part of a holistic wellness regimen that will keep inflammation and disease at bay, or at least slow it down the way it works with Parkinson’s and Alzheimer’s.

Whether you choose to get high or not, use it as medicine or for recreation, there are some things that seniors should keep in mind when using cannabis for the first time:

e-mail icon
Continue reading

Could CBD help people with diabetes?

 

From a strictly prohibited substance to a so-called ‘miracle drug’, clinical and cultural interest in CBD is on the rise.

As the data in favour of its healing power continues to trickle in, the list of the medical conditions in which CBD could offer therapeutic relief is only getting longer.

Some researchers even believe that CBD could help to manage one increasingly prevalent and potentially life-threatening condition: diabetes. The hard evidence is lacking, but the testimonials are there; could CBD really help people living with diabetes?

Diabetes: an overview

Diabetes is a chronic condition that affects blood sugar levels. It occurs when the body doesn’t make enough (or any) insulin, a hormone made by the pancreas that helps the body to break down sugar for energy. This results in the blood glucose levels being too high, which causes a range of uncomfortable symptoms, including:

Being really thirstyPeeing a lot, particularly at nightFeeling very tiredUnexplained weight loss 

Diabetes affects over 4.9 million people in the UK. There are two major types of diabetes, type 1 and type 2. Type 1 diabetes is a lifelong autoimmune condition where the immune system attacks the cells that produce insulin, meaning the body is unable to produce insulin. Around 8% of people with diabetes in the UK have type 1.  

Type 2 diabetes is far more common; it accounts for over ​​90% of UK diabetes cases. With type 2 diabetes, the pancreas still releases insulin, but it either isn’t enough or doesn’t work properly. According to the NHS, you can manage type 2 diabetes with healthy eating, regular exercise and achieving a healthy body weight.

e-mail icon
Continue reading

More Ohioans could become eligible for medical marijuana under Senate bill

 

 

A Republican lawmaker’s efforts to overhaul Ohio’s medical marijuana program and expand the number of Ohioans eligible for a cannabis prescription was put to the test Wednesday.

The House Government Oversight Committee held its fourth hearing on Senate Bill 261, introduced by Sen. Steve Huffman (R-Tipp City), to streamline the process for businesses vying for a medical marijuana license and permit physicians to prescribe the drug where they “reasonably” believe it will help a patient.

“It makes it more patient-centered, and as a physician, I’ve always been for making it patient-centered, that they can get it for the right conditions and the right way for a good price,” Huffman said.

Under current law, Ohio’s medical marijuana program falls under the purview of the Ohio Board of Pharmacy. Huffman’s bill would transfer most of the authority to the Department of Commerce – a move he said will spur the provision of business licenses at a quicker pace to keep up with the market’s demand.

Huffman said businesses seeking a license are often bounced back and forth between the Ohio Board of Pharmacy and the Department of Commerce, so SB 261 would eliminate the bureaucratic red tape around the process.

“It all moves over to the commerce department to provide one uniform place for businesses to get their answers and develop their business,” he said.

e-mail icon
Continue reading

Cannabis patients aren’t addicts: it’s time to let that fear go

If you cast your eyes back to articles published recently on the Volteface website, you’ll find one entitled ‘We need to talk about cannabis dependency’.

The author is completely right of course – we do need to talk about it. Cannabis dependency and the potential to abuse cannabis is a very real problem for some and, perhaps of equal importance, it’s a problem which stands firmly at the forefront of arguments against improving access to medical cannabis or indeed, changing cannabis legalisation and regulation as a whole.

If you wish to advocate for cannabis and those who choose to use cannabis, it’s vital that this concern is well understood and addressed – it helps no-one to act as though this issue doesn’t exist. However, a large part of the reason why most people who are unsure about the safety of cannabis or against the idea of making legal cannabis more accessible in the U.K feel this way not because of a balanced review of the facts or a worry that is backed up by science. It’s a direct result of media-fuelled moral panic and a century of anti-cannabis propaganda, much of which is hooked on the risk of addiction and potential damage to mental health.

Because of this, I feel it’s essential to delve into the nuance of this fear and understand how likely addiction to and abuse of cannabis really is, particularly for patients using the drug medicinally. 

When cannabis is prescribed by a clinician, addiction and abuse are extremely unlikely to arise. In this situation, you are using cannabis under guidance – following dosage instructions, using a CBD:THC oil blend formulated and titrated to suit your needs, or cannabis flower chosen carefully to treat particular symptoms or conditions. Most people using cannabis for a medicinal purpose don’t want to get high – they just want to feel well. It’s key to making cannabis widely available to those who need it that we all realise this. 

Incredibly, cannabis actually has the potential to be effective for treating a wide range of conditions in very small doses. One study, performed by Dr Mark Ware et al, demonstrated that a low dose of 25mg of herbal cannabis with 9.4% THC, taken spread out in single inhalations 3 times a day, resulted in significant improvements in pain, sleep, mood, appetite, stiffness and nausea, compared to placebo. However, in the trial, there were only 3 episodes of euphoria. None of the other participants described feeling ‘high’ as a side effect.

e-mail icon
Continue reading

Lawsuit claims Georgia medical marijuana licenses clouded by back room deals

A medical marijuana company has filed a lawsuit against the Georgia Access to Medical Cannabis Commission alleging the evaluations and scoring of medical cannabis bid applications was clouded by "conflicts of interest" and licenses were "bought and sold through closed door politics and back room deals."

"If there is no wrong doing or corruption, then why not turn these applications, evaluation sheets, etc. over to the public," said Cumberland Curative President Charlie Arnold.

Arnold believes his company was cheated out of an honest chance to win one of the first ever licenses to legally grow and produce medical marijuana in Georgia.

Cumberland Curative filed a lawsuit in Fulton County Superior Court against the Georgia Access to Medical Cannabis Commission claiming essentially – where there is smoke there is fire.

The lawsuit claims the scoring of bids was "clouded by substantial conflict of interest" and that licenses were "bought and sold through closed – door politics and back-room deals."

And the Cumberland Curative president said he can back it up.

e-mail icon
Continue reading

Can cannabis treat autism?

Studies continually show great potential for cannabis as an effective treatment for autism. Determining the right dose, however, is proving difficult.

Fewer and fewer places in the US remain where it’s still a criminal act for adults 21 and older to use cannabis. Even fewer places deny sick Americans (with the right sickness to qualify them as medical marijuana patients) some accommodation to use cannabis lawfully. But even these 14 cannabis legalization holdouts agree that it’s OK to give marijuana extracts to kids, as long as those kids have been diagnosed with an autism spectrum disorder. And with good reason. Miraculous stories are all over the internet, such as children speaking their first words after using cannabis oil, or autistic adults with severe anxiety and near-total social isolation rejoining society after smoking cannabis. So, this begs the question, “Can cannabis ‘treat’ autism?”

A definitive final answer is elusive. However, as a review authored by researchers led by Mariana Babayeva, a professor at the Touro College of Pharmacy in New York and recently published in the scientific journal Frontiers in Bioscience found, a growing number of “clinical studies have shown promising results of cannabis treatment in” autism spectrum disorder (ASD).

How Cannabis Helps Autism

This makes practical and scientific sense. CBD and THC activate the network of receptors called the endocannabinoid system. “Due to its vital role in regulating emotion and social behaviors, the endocannabinoid system represents a potential target for the development of a novel autism therapy,” the study states.

Cannabis does help autism, as this latest review, prior studies and loads of compelling, convincing anecdotal stories say. But what cannabis treatment would work best for each individual case of autism, and how much cannabis should be given in those instances?

“It’s too early for anyone to recommend cannabis as a validated, well-studied type of a substance,” said Dr. Nathan Call, director of clinical operations at the Marcus Autism Center in North Druid Hills, Georgia, in a recent interview.

e-mail icon
Continue reading

House bill adds quadriplegia for medical cannabis use in Tennessee

 

Lawmakers are trying to expand the use of medical cannabis in Tennessee with one saying he can personally benefit from its use.

House Bill1747 adds quadriplegia as a qualifying medical condition for the lawful possession of cannabis oil.

“Members, I live with this diagnosis every day,” said the bill’s sponsor Representative Darren Jernigan (D-District 60) whose district includes the Old Hickory community of Davidson County.

The proposed legislation allows the Medical Cannabis Commission to study the effects and give lawful possession of cannabis oil to Tennesseeans who are quadriplegic. The current diagnoses on the list include Alzheimer’s, ALS, cancer, epilepsy, HIV, and sickle cell.

Representative Jernigan said adding quadriplegia to the list can help with the most common side effects like severe muscle spasms, chronic pain, overactive bladders, and insomnia.

“I’m in a chair sometimes 12 to 14 hours a day. At that point in time I can receive severe muscle spasms that are really stressful on my body that leads to insomnia,” Jernigan said. “I’ve exhausted all conventional treatments that are out there. I don’t smoke marijuana. I don’t get high. That’s not the intention of this. Law enforcement is deferred on this bill and with that explanation Mr. Speaker I renew my motion.”

e-mail icon
Continue reading

Sustainable solutions: How hemp is being used to make prosthetic limbs

Kyle Trivisonno is one of the brains at Human Plant Solutions. He's currently working on a project that uses hemp to make prosthetic limbs.

“Having something that moves and kind of transitions with their gate cycle is kind of an ideal property," Trivisonno said.

There are more than 2 million Americans who have lost an arm or a leg or were born without one of their limbs. Millions more have health issues, such as diabetes, that could lead to amputation in the future.

Trivisonno and Sam Spallita have devoted their new business to providing an alternative to high-cost options.

“In general, I think that there are a lot of ways for a company like mine that really wants to provide solutions, especially customized solutions with innovative materials. I mean the door is wide open for us to make water foots, swimming adapting thing and we really want to do that and make it cost-effective," Spallita said.

“Everybody hates carbon fiber. You’ve got to wear a suit and full respiration and still with all that PPE on. I don’t care what ventilation you have you’re still going to be covered in that carbon dust which is extremely dangerous to work with and really just not comfortable," Trivisonno said.

e-mail icon
Continue reading

New app shows how cannabinoids could interact with other medications

 

A new web-based application developed by Penn State researchers could help pharmacists and other health care providers improve patient safety by reducing unintended interactions between medical and recreational marijuana and cannabidiol (CBD) products and other medications. Penn State College of Medicine researchers said that medical marijuana and CBD have become more accessible to consumers through local retail stores, pharmacies or even by illicit means, and that these products may affect the metabolism of other medications.

CANNabinoid Drug Interaction Review (CANN-DIR) is a free web-based resource that evaluates cannabinoid products such as delta-9-tetrahydrocannabinol (THC), CBD or a combination of both (THC and CBD) in a single product against a database of common over-the-counter and prescription medications. CANN-DIR was developed by researchers at the College of Medicine, which is one of nine approved medical marijuana Academic Clinical Research Centers in Pennsylvania.

Users select the cannabinoid product a patient is taking and then choose other medications they are using. CANN-DIR then provides information about how the THC and/or CBD product could potentially affect the metabolism, or breakdown, of the other selected medications.

Kent Vrana, Elliot S. Vesell Professor and Chair of the Department of Pharmacology and project leader, said it’s important for health care professionals and patients to understand that cannabinoid products, whether prescribed or used recreationally, may influence the activity of other medications. For example, drugs like warfarin, often used to prevent blood clots, have a narrow therapeutic index in which small differences in the amount of active ingredient in the blood could lead to therapeutic failure or adverse events, such as bleeding.

“Some drugs can affect the way others are broken down by the body, which can be problematic in the case of medications with a narrow therapeutic index,” Vrana said. “People may not realize that THC and CBD products have the ability to change the way other drugs are metabolized, and it’s an important conversation for patients and health care providers to have with each other. CANN-DIR can help facilitate those conversations and provide useful information for health care providers when prescribing medications to their patients.”

The information in the CANN-DIR database was researched by Vrana and Paul Kocis, a clinical pharmacist at Penn State Health Milton S. Hershey Medical Center. Funding from the Center for Medical Innovation at the College of Medicine enabled Vrana and Kocis to connect with Penn State Harrisburg computer science students Samuel Wadrose, Aqib Ahmed and Rohan Gajjar, who worked on the app as part of their capstone project last spring. With mentoring from their academic adviser, Hyuntae Na, assistant professor in the School of Science, Engineering and Technology, the team launched the first version of the app on March 22. Currently, another group of computer science students are working on version 2, which the researchers plan to be more user friendly for patients and their caregivers.

e-mail icon
Continue reading

The demand for medical cannabis in Israel is growing like a weed

 

When it comes to emerging international cannabis markets, Israel is one of the first countries to come to mind. (Technical 420)

From researching medical cannabis for more than 50 years to being able to cultivate for a fraction of the cost in North America, we are bullish on the economics and the long-term growth prospects that are associated with the Israeli market.

In mid-2020, Israel overtook Germany as the largest importer of medicinal cannabis in the world (according to data from Tel Aviv-based Cannabis Magazine and Marijuana Business Daily) and have noticed increased interest in the region as a result.

According to cultivation data from several large-scale Canadian Licensed Producers (LPs) which are levered to Israel, the all-in cost per gram of cannabis flower is less than $0.40 in the country. Due to the low cultivation costs, we find the economics of Israel’s cannabis industry to be very attractive and believe our readers should be aware of this. 

Another reason we are excited about the Israeli cannabis market is related to the export opportunity to the European Union (EU). From a geographic standpoint, Israel is located much closer to the EU than Canada. As a result, shipping costs from Israel to the EU are lower than shipping costs from Canada to the EU. 

So far this year, we have seen a spike in the amount of demand for medical cannabis in Israel and are working to identify companies that are benefiting from this. Some of the Canadian LPs that are focused on Israel are Aurora Cannabis Inc. (TSX: ACB) (Nasdaq: ACB), IM Cannabis Corp. (CSE: IMCC) (Nasdaq: IMCC), Aleafia Health Inc. (TSX: AH) (ALEAF), and Cronos Group Inc. (Nasdaq: CRON) (TSX: CRON). (Click Here to View the Entire Article)

Rate this article: 
Select ratingGive The demand for medical cannabis in Israel is growing like a weed 1/5Give The demand for medical cannabis in Israel is growing like a weed 2/5Give The demand for medical cannabis in Israel is growing like a weed 3/5Give The demand for medical cannabis in Israel is growing like a weed 4/5Give The demand for medical cannabis in Israel is growing like a weed 5/5
Authored By: 
Article category: 
Regional Marijuana News: 

e-mail icon

It's not just dogs: All sorts of pets are being poisoned by marijuana

More pets are being poisoned by marijuana plants and edibles than in the past and some even die, a new study finds.

A survey of veterinarians found cases of poisoning occurred most frequently in dogs, but cats, iguanas, ferrets, horses and cockatoos also fell victim to the hallucinogenic effects of marijuana.
"Most cases of cannabis toxicity was via oral route of delivery, by ingesting edibles or discarded joint butts or dried plant materials," said study author Jibran Khokhar, an assistant professor in the Ontario Veterinary College at the University of Guelph in Ontario, Canada.
"It's important to remember our pets are not tiny people. They're very different creatures with different metabolisms and because of that they can have serious outcomes from ingesting marijuana," said Dr. Dana Varble, the chief veterinary officer for the North American Veterinary Community.
"The effects on a small animal will be much stronger than what you or I might experience," said Varble, who was not involved in the study.
 
"For a dog or cat that really doesn't understand why they might feel a certain way, we certainly see disorientation, distress and anxiety," she said.
There's a double danger, she added. Many of today's edibles come packaged in chocolate and fruit flavors, which are very appealing to dogs and even cats, she said. Chocolate, grapes, raisins and citrus are toxic to dogs and cats, as is the sweetener xylitol that may be used in marijuana gummies.
 
"Now we have a dog or cat that's not only suffering from the toxic effects of THC, but also a multi-drug toxicity," Varble said.
 
"That certainly complicates treatment for the animal and adds anxiety and expense for the pet parent."
 

Willingness to report

The study, published Wednesday in the journal PLOS ONE, surveyed veterinarians in Canada and the United States about their experiences with cannabis poisonings after Canada and a number of US states had legalized marijuana.
 
Veterinarians reported a rise in cases, which could be due to increased access to legal marijuana products in some US states and Canada, which legalized cannabis in 2018. It might also be due to more people being willing to report the real reason for their pet's symptoms, Khokhar said.
 
"When the drug is legalized, more people are going to be willing to report," Khokhar said. "In the past they might have come in with the same issue and said, 'I don't know what happened to my pet.' "
 
Most people told their veterinarian the exposure happened accidentally, the survey found.
 
"However, I don't think we can rule out intentional use, either for recreational purposes or medicinal purposes," Khokhar said, pointing to videos on social media that show people intentionally giving marijuana to their dogs or cats.
 
"People may also be giving THC or CBD to their pet for medicinal purposes, but there's a handful of indications that CBD actually works for -- everything else is hooey," he said.
 
"Cannabis-based medicine is not approved for veterinary use."
 
The most common symptoms in pets exposed to cannabis included disorientation, lethargy, abnormal or uncoordinated movements such as swaying, lowered heart rate and urinary incontinence.
 
"The animals peed everywhere," Khokhar said. "And the last was increased sensitivity of the senses -- everything from sensitivity to light, to startling when touched or when they heard a sound."
 
Most pets recovered, sometimes after 24 to 48 hours in the vet hospital, the study found. Sixteen dogs died after ingesting marijuana, he said, but "it's hard to assess whether the death was related to the cannabis itself or other ingredients in the cannabis edible, such as chocolate."
Pet owners should be extremely cautious about keeping pets away from any product with marijuana, by storing them in locked containers and in places the pet cannot access, Varble said.
 
"The other thing pet owners have to remember is that those lovely childproof bottles that we keep prescription medications in are not dog-proof," she added.
 
"Anyone who's ever seen a dog chew up a plastic toy or a shoe can see how easily that can happen."
 
 
Rate this article: 
Select ratingGive It's not just dogs: All sorts of pets are being poisoned by marijuana 1/5Give It's not just dogs: All sorts of pets are being poisoned by marijuana 2/5Give It's not just dogs: All sorts of pets are being poisoned by marijuana 3/5Give It's not just dogs: All sorts of pets are being poisoned by marijuana 4/5Give It's not just dogs: All sorts of pets are being poisoned by marijuana 5/5
Authored By: 
Article category: 
Regional Marijuana News: 

e-mail icon

Laughlin pushes for pot edibles at Pennsylvania dispensaries

Pennsylvania's medical marijuana program could offer up pot edibles down the road if a state senator representing the Erie area gets his way.

Republican Dan Laughlin is introducing a bill to allow medical marijuana patients in the state to buy cannabis edibles at dispensaries.

Laughlin said it will bring Pennsylvania in line with the majority of states that have legalized medical marijuana.

He said his bill will include specific steps to make sure that cannabis edibles are designed in a way that does not appeal to children.

Meanwhile, a key Pennsylvania senate committee held the last of three scheduled hearings on recreational marijuana legalization last month.

Rate this article: 
Select ratingGive Laughlin pushes for pot edibles at Pennsylvania dispensaries 1/5Give Laughlin pushes for pot edibles at Pennsylvania dispensaries 2/5Give Laughlin pushes for pot edibles at Pennsylvania dispensaries 3/5Give Laughlin pushes for pot edibles at Pennsylvania dispensaries 4/5Give Laughlin pushes for pot edibles at Pennsylvania dispensaries 5/5
Authored By: 
Regional Marijuana News: 

e-mail icon

Cannabis hyperemesis syndrome – what you need to know

Despite the extraordinary progressions in cannabis medicine and the necessary push for changes to its legislation, advocates should not be blind to the very real – and often serious – complications of excessive cannabis use. As they say, too much of anything is good for nothing.

Holding an unreservedly positive view of this plant allows us only to overlook any unwanted effects, which would actually do far more harm than good. We’re here to help you better understand cannabis hyperemesis syndrome – a rare, but damaging, potential side effect of using cannabis. 

What is cannabis hyperemesis syndrome?

Cannabis hyperemesis syndrome, or CHS for short, is a condition that occurs in people with a long history of cannabis use. It is characterised by:

NauseaVomitingAbdominal pain

Taking regular hot showers or baths as a way to soothe nausea is another indicator of having CHS.

The symptoms of CHS can be grouped into three separate phases. The first is the prodromal phase, where the individual experiences nausea, abdominal discomfort, and potentially anxiety due to a fear of vomiting. The second is the hyperemetic phase, characterised by vomiting, dehydration, and weight loss. In the days or months following cannabis cessation is the recovery phase, where CHS symptoms subside. 

e-mail icon
Continue reading

Cannabis and pancreatic cancer: Botanical drug kills 100% of cancer cells

A botanical drug based on an extract of Cyathus striatus fungus and a cannabinoid extract from the cannabis plant has eliminated 100% of pancreatic cancer cells—relatively selectively and without damaging normal cells—in experiments conducted on a cell model.

The fungus has been the subject of research to test its anti-cancer efficacy in Professor Fuad Fares’ laboratory at the University of Haifa for about eight years.

It was selected as the preferred candidate for the development of a drug for pancreatic and colon cancer after showing better anti-cancer results than a variety of other fungi tested.

A few months ago, the biomedical company Cannabotech received global and exclusive rights of use for patents created in Prof. Fares’ research and began leading an accelerated process of developing a botanical drug as defined by the FDA.

A new milestone

The first milestone in the botanical drug development process was defined as the adaptation of fungal growth and extraction methods to the FDA protocol for botanical drug development, which the company expects to be significantly cheaper and shorter than the development process of a standard ethical drug.

e-mail icon
Continue reading

This line of vegan products single-handedly cured my stress acne

Hey Bud specializes in hemp-based skincare—a godsend for combination skin like mine.

Anyone who's been within five feet of me recently has had the absolute pleasure of hearing me complain about my stress acne. About a month ago, I began an arduous move from Boston to New York City, and, having moved around frequently during my adult life, I knew exactly what that transition meant for my skin: Lots of stubborn blemishes on my cheeks, forehead, and chin that take ages to go away and result in hyperpigmentation. At first, I resigned myself to this inevitability, and when I received Hey Bud Skincare's Glow Up Bundle, I thought, "Why not? These products can't possibly make my skin any worse." Lo and behold, they did not make it worse—they made it unbelievably better.

Hey Bud is a vegan, organ, cruelty-free, and gluten-free brand whose products are based in hemp oil, which is derived from the cannabis sativa plant. The brand promises that its products help smooth aging skin and control oil production without stripping skin of its moisture. In short, hemp-based skincare is meant to be the ideal cure-all for combination skin like mine, because it seeks restore balance by moisturizing dry spots and curbing the excess sebum production that results in acne.

Filled with tentative hope, I started by trying the Daily Hemp Gel Cleanser. The lightweight formula definitely made my face feel clean and relieved of its greasiness, particularly after coming back from a workout, but I also didn't feel too dry in the way I sometimes do after using products heavy in salicylic acid. Similarly, the Hemp Moisturizer felt light and dried matte on my face, but also provided substantial moisture. 

Hey Bud Daily Hemp Gel Cleanser

Hey Bud Hemp Moisturizer

The next product in the bundle—and the one I was most nervous about trying—was the face oil. Being that I tend to break out when I'm stressed, I didn't want to add any more oil to my skin, but I also know that ultra-dry skin can worsen breakouts by causing skin to ramp up oil production. Plus, the spot treatment I'd been using on my zits was starting to make certain areas of my skin flake, so I needed a moisture boost fast.

The face oil was a perfect option. It's rich enough to feel luxurious and heavily moisturizing, as intended, but it also doesn't make me look shiny or leave residue on my pillow when I go to bed. Personally, I like it best for use at night, as a follow-up to the thick Hemp Clay Mask.

Speaking of the mask, it is very much a clay mask in that it's thick, creamy, and oil-reducing. I recommend ensuring that your face is nice and moisturized before using the mask, or your skin will sting, but when your face (or back, or chest, or anywhere) is feeling particularly oily, this mask is an excellent option. I felt like I was giving my skin a fresh, clean new start after wiping it off. The mask also comes with a cute little brush so that I don't have to poke at my face with my fingers when I apply the formula once a week. 

e-mail icon
Continue reading

Here’s how many medicare patients use marijuana, even though it’s not covered

Medicare users are over the age of 65, a demographic that coincides with a lot of medical marijuana users.

A new report shows that Medicare users and medical marijuana patients have a lot in common. According to a survey reported by U.S. News, 1 in every 5 Medicare patients use medical cannabis. Cannabis is not covered by Medicare in any state. The survey, which was conducted on 1,250 Medicare recipients, also found that 23% of them had used cannabis in the past. Out of all recipients, 21% of them use medical cannabis to treat an ailment.

According to the survey, patients used medical marijuana primarily to treat anxiety, closely followed by chronic pain. Other conditions that were submitted include depression, glaucoma, symptoms of HIV, like nausea, depression, and more. Two-thirds of respondents said they agreed with a statement that said that medical marijuana should be covered by Medicare.

Interestingly enough, current medical marijuana users aren’t too keen on having Medicare cover cannabis. They believe Medicare coverage could increase the price of the product, resulting in them paying more in the long run for the product they want to consume.

Lastly, 31% of Medicare users oppose Medicare’s coverage of marijuana, quoting a lack of research and knowledge on the drug as the main reason for their reticence.

Medicare is federal health insurance for people over the age of 65, a demographic that includes a lot of medical marijuana users. In recent years, seniors have increased their medical marijuana use steadily, coinciding with the legalization of cannabis across the country.

e-mail icon
Continue reading

Recreational marijuana access reduces demand for prescription drugs

Legalization of recreational marijuana reduces demand for costly prescription drugs through state Medicaid programs, according to an analysis by a Cornell researcher and a collaborator.

When states legalize marijuana, the volume of prescriptions within the drug classes that align with the medical indications for pain, depression, anxiety, sleep, psychosis and seizures significantly decline, the researchers found.

Shyam Raman, a doctoral student in the Cornell Jeb E. Brooks School of Public Policy, and Indiana University doctoral student Ashley Bradford conducted the research. Their article, “Recreational Cannabis Legalizations Associated with Reductions in Prescription Drug Utilizations Among Medicaid Enrollees,” published April 15 in the journal Health Economics.

Most cannabis research has focused on the impact of medical marijuana on demand for prescription drugs or the impact of recreational use legalization on opioid demand. This is among the first studies to focus on the impact of legal personal-use cannabis on a broad range of prescription drugs.

“These results have important implications,” Raman said.

e-mail icon
Continue reading

WeedLife.com